Developments include drug delivery methods, focus on ocular hypertension and neuroprotection
An evolution in glaucoma therapy is underway, shifting from a reliance solely on medication and surgery, to a greater understanding of disease pathology and risk factors in the conversion of ocular hypertension to glaucoma. In addition, there is a growing interest in new diagnostic technologies that will facilitate evaluation of the optic nerve, nerve fibre layer and macula, said Dr Murray Fingeret, FAAO, at SECO 2012.
Preservative-free formulas
Tafluprost is the first preservativefree prostaglandin analogue. Dorzolamide hydrochloride-timolol maleate is a fixed combination containing a carbonic anhydrase inhibitor and beta-adrenergic receptor blocking agent.
"The question is whether this is a leap forward in terms of efficacy, and we really don't know yet," he said. Tafluprost is expected to be comparable in IOP-lowering efficacy to other prostaglandins, with fewer effects on the ocular surface.
A plus for compliance?
Dr Fingeret noted that both new drugs are packaged in unit doses, with the cost and 'hassle' of using single-dose vials potentially influencing patient compliance.
"If they have enough motivation, patients will use them, while others may not want to," Dr Fingeret said. "One potential advantage is in having one vial for each day; this will prevent patients from using too many drops and running out before the month is out."
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Evaluating the clinical performance of ZEISS AT ELANA and the new ’ELISA’* approach
July 30th 2025In this insightful analysis, Dr. Joong Hun Kim presents real-world clinical outcomes with bilateral implantation of ZEISS AT ELANA 841P. Dr. Kim recommends AT ELANA® 841P as an excellent option for patients undergoing cataract surgery as its fully trifocal optical design translates into a full range of vision. He also introduces the so-called ‘ELISA’ approach for patients requiring astigmatic correction in one eye only, combining AT ELANA 841P and ZEISS AT LISA tri toric 939MP. Early objective and subjective clinical data from this novel approach reveal promising visual outcomes and high patient satisfaction